Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2016

01-10-2016 | Original Article

Inhibition on Numb/Notch signal pathway enhances radiosensitivity of lung cancer cell line H358

Authors: Shi-Gang Song, Hong-Yang Yu, Yan-Wei Ma, Feng Zhang, Xiang-Ying Xu

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

The objective of the study is to investigate the effects of the Numb/Notch signal pathway on the radiosensitivity of lung cancer cell line H358. MTT assay and colony forming assay were used to detect the effects of different doses of X-rays and MW167 on the in vitro proliferation of the lung cancer cell line H358. Flow cytometry was applied to evaluate the effects of X rays on the apoptosis of H358. Scratch assay and Transwell invasion assay were used to examine the effects of X-rays on the migration and invasion abilities of H358. The mRNA and protein expressions in the signal pathway were detected by real-time PCR and western blot. Assays in vitro confirmed the effects of the Numb/Notch pathway inhibitor on the radiosensitivity to lung cancer. MW167 enhanced the inhibiting effects of X-ray on the proliferation of H358 cell line. After the addition of MW167, the apoptosis rates significantly increased, but the invasion and migration abilities decreased significantly. Meanwhile, MW167 could dose-dependently promote the increase of expression of Numb, which is the upstream gene of the Numb/Notch signaling pathway, but inhibit the expression of and HES1. In vivo experiments revealed that cell proliferation was suppressed in the radiation, pathway inhibitor, and pathway inhibitor + radiation groups, and the pathway inhibitor + radiation group exhibited more active anti-tumor ability when compared with the blank group (all P < 0.05); Numb expression was up-regulated, but Notch1 and HES1 expressions were down-regulated in those three groups, and also, the pathway inhibitor + radiation group exhibited more significant alternation when compared with the blank group (all P < 0.05); cell apoptosis was promoted in those three groups, and the pathway inhibitor + radiation group showed more active apoptosis when compared with the blank group (all P < 0.05). Repression of the Numb/Notch pathway enhances the effects of radiotherapy on the radiosensitivity of the lung cancer cell line H358, and thus the Numb/Notch pathway may be a new target of radiotherapy for lung cancer.
Literature
1.
Wang GF, Lai MD, Chen PH. Correlation of multiple primary lung cancer with bronchial and alveolar epithelial dysplasia. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2005;34(5):427–31.PubMed
2.
3.
4.
Xie SS, Li M, Zhou CC, Song XL, Wang CH. Prophylactic cranial irradiation may impose a detrimental effect on overall survival of patients with nonsmall cell lung cancer: a systematic review and meta-analysis. PLoS One. 2014;9(7):e103431.CrossRefPubMedPubMedCentral
5.
Hillman GG, Singh-Gupta V, Runyan L, Yunker CK, Rakowski JT, Sarkar FH, et al. Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury. Radiother Oncol. 2011;101(2):329–36.CrossRefPubMedPubMedCentral
6.
Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39–85.CrossRefPubMed
7.
Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase b is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61(10):3986–97.PubMed
8.
Wang XC, LQ D, Tian LL, HL W, Jiang XY, Zhang H, et al. Expression and function of mirna in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer. 2011;72(1):92–9.CrossRefPubMed
9.
Zhou C, YL W, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced egfr mutation-positive non-small-cell lung cancer (optimal, ctong-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.CrossRefPubMed
10.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.CrossRefPubMedPubMedCentral
11.
Wharton KA, Johansen KM, Xu T, Artavanis-Tsakonas S. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing egf-like repeats. Cell. 1985;43(3 Pt 2):567–81.CrossRefPubMed
12.
Kidd S, Kelley MR, Young MW. Sequence of the notch locus of Drosophila melanogaster: relationship of the encoded protein to mammalian clotting and growth factors. Mol Cell Biol. 1986;6(9):3094–108.CrossRefPubMedPubMedCentral
13.
Lai EC. Notch signaling: control of cell communication and cell fate. Development. 2004;131(5):965–73.CrossRefPubMed
14.
Leong KG, Karsan A. Recent insights into the role of notch signaling in tumorigenesis. Blood. 2006;107(6):2223–33.CrossRefPubMed
15.
Zhang XP, Zheng G, Zou L, Liu HL, Hou LH, Zhou P, et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem. 2008;307(1–2):101–8.PubMed
16.
Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6(6):R605–15.CrossRefPubMedPubMedCentral
17.
Dho SE, French MB, Woods SA, McGlade CJ. Characterization of four mammalian numb protein isoforms. Identification of cytoplasmic and membrane-associated variants of the phosphotyrosine binding domain. J Biol Chem. 1999;274(46):33097–104.CrossRefPubMed
18.
Pece S, Confalonieri S, RR P, Di Fiore PP. Numbing down cancer by more than just a notch. Biochim Biophys Acta. 2011;1815(1):26–43.PubMed
19.
Gulino A, Di Marcotullio L, Screpanti I. The multiple functions of numb. Exp Cell Res. 2010;316(6):900–6.CrossRefPubMed
20.
Tosoni D, Zecchini S, Coazzoli M, Colaluca I, Mazzarol G, Rubio A, et al. The numb/p53 circuitry couples replicative self-renewal and tumor suppression in mammary epithelial cells. J Cell Biol. 2015;211(4):845–62.CrossRefPubMedPubMedCentral
21.
Katoh M, Katoh M. Numb is a break of Wnt-notch signaling cycle. Int J Mol Med. 2006;18(3):517–21.PubMed
22.
Westhoff B, Colaluca IN, D’Ario G, Donzelli M, Tosoni D, Volorio S, et al. Alterations of the notch pathway in lung cancer. Proc Natl Acad Sci U S A. 2009;106(52):22293–8.CrossRefPubMedPubMedCentral
23.
Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of notch signaling in cancer. Oncogene. 2008;27(38):5124–31.CrossRefPubMed
24.
Cook J. Radiation sensitization of mammalian cells by metal chelators. Radiat Res. 2001;155(2):304–10.CrossRefPubMed
25.
Jia S, Zhang S, Yuan H, Chen N. Lunasin inhibits cell proliferation via apoptosis and reduces the production of proinflammatory cytokines in cultured rheumatoid arthritis synovial fibroblasts. Biomed Res Int. 2015;2015:346839.PubMedPubMedCentral
26.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
27.
Meder L, Konig K, Ozretic L, Schultheis AM, Ueckeroth F, Ade CP, et al. Notch, ascl1, p53 and rb alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer. 2016;138(4):927–38.CrossRefPubMed
28.
29.
Wang G, Mao W, Zheng S, Ye J. Epidermal growth factor receptor-regulated mir-125a-5p—a metastatic inhibitor of lung cancer. FEBS J. 2009;276(19):5571–8.CrossRefPubMedPubMedCentral
30.
Cron KR, Zhu K, Kushwaha DS, Hsieh G, Merzon D, Rameseder J, et al. Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer. PLoS One. 2013;8(9):e73710.CrossRefPubMedPubMedCentral
31.
Jiang L, Chang J, Zhang Q, Sun L, Qiu X. MicroRNA hsa-mir-125a-3p activates p53 and induces apoptosis in lung cancer cells. Cancer Investig. 2013;31(8):538–44.CrossRef
32.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage iiia or iiib non-small-cell lung cancer (rtog 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.CrossRefPubMedPubMedCentral
33.
Yan B, Omar FM, Das K, Ng WH, Lim C, Shiuan K, et al. Characterization of numb expression in astrocytomas. Neuropathology. 2008;28(5):479–84.CrossRefPubMed
34.
Zhao YJ, Han HZ, Liang Y, Shi CZ, Zhu QC, Yang J. Alternative splicing of VEGFA, app and numb genes in colorectal cancer. World J Gastroenterol. 2015;21(21):6550–60.CrossRefPubMedPubMedCentral
35.
Wang C, Feng W, Zhang C. The expression and function of numb in endometrial cancer and the interaction with hdm2 and p53. J Cancer. 2015;6(10):1030–40.CrossRefPubMedPubMedCentral
36.
Zhang XM, Wang JX, Lei XG, Cheng H, Wang LL, Yao GY. Regulation and mechanism of notch signaling pathway in small cell lung cancer. Zhonghua Bing Li Xue Za Zhi. 2010;39(2):95–9.PubMed
37.
McGill MA, Dho SE, Weinmaster G, McGlade CJ. Numb regulates post-endocytic trafficking and degradation of notch1. J Biol Chem. 2009;284(39):26427–38.CrossRefPubMedPubMedCentral
38.
Zhou P, Alfaro J, Chang EH, Zhao X, Porcionatto M, Segal RA. Numb links extracellular cues to intracellular polarity machinery to promote chemotaxis. Dev Cell. 2011;20(5):610–22.CrossRefPubMedPubMedCentral
39.
Nickoloff BJ, Qin JZ, Chaturvedi V, Denning MF, Bonish B, Miele L. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through nf-kappab and PPAR-gamma. Cell Death Differ. 2002;9(8):842–55.CrossRefPubMed
40.
Pitsouli C, Delidakis C. The interplay between DSL proteins and ubiquitin ligases in notch signaling. Development. 2005;132(18):4041–50.CrossRefPubMed
41.
Okajima T, Irvine KD. Regulation of notch signaling by o-linked fucose. Cell. 2002;111(6):893–904.CrossRefPubMed
42.
Gordon WR, Vardar-Ulu D, Histen G, Sanchez-Irizarry C, Aster JC, Blacklow SC. Structural basis for autoinhibition of notch. Nat Struct Mol Biol. 2007;14(4):295–300.CrossRefPubMed
43.
Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, et al. A novel proteolytic cleavage involved in notch signaling: the role of the disintegrin-metalloprotease tace. Mol Cell. 2000;5(2):207–16.CrossRefPubMed
44.
45.
Gupta-Rossi N, Six E, LeBail O, Logeat F, Chastagner P, Olry A, et al. Monoubiquitination and endocytosis direct gamma-secretase cleavage of activated notch receptor. J Cell Biol. 2004;166(1):73–83.CrossRefPubMedPubMedCentral
46.
Nam Y, Sliz P, Pear WS, Aster JC, Blacklow SC. Cooperative assembly of higher-order notch complexes functions as a switch to induce transcription. Proc Natl Acad Sci U S A. 2007;104(7):2103–8.CrossRefPubMedPubMedCentral
47.
Yao J, Duan L, Fan M, X W. Gamma-secretase inhibitors exerts antitumor activity via down-regulation of notch and nuclear factor kappa b in human tongue carcinoma cells. Oral Dis. 2007;13(6):555–63.CrossRefPubMed
48.
Zhou M, Fan Z, Han R. Influence of blocking notch signaling pathway by γ-secretase inhibitor on proliferation of lung adenocarcinoma a549 cells. J Shanghai Jiaotong Univ (Med Sci). 2012;8(021).
49.
Mizugaki H, Sakakibara-Konishi J, Ikezawa Y, Kikuchi J, Kikuchi E, Oizumi S, et al. Gamma-secretase inhibitor enhances antitumour effect of radiation in notch-expressing lung cancer. Br J Cancer. 2012;106(12):1953–9.CrossRefPubMedPubMedCentral
50.
Kang J, Kim E, Kim W, Seong KM, Youn H, Kim JW, et al. Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (emt) by mir-34a-mediated suppression of notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem. 2013;288(38):27343–57.CrossRefPubMedPubMedCentral
51.
Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010;28(1):17–28.PubMedPubMedCentral
Metadata
Title
Inhibition on Numb/Notch signal pathway enhances radiosensitivity of lung cancer cell line H358
Authors
Shi-Gang Song
Hong-Yang Yu
Yan-Wei Ma
Feng Zhang
Xiang-Ying Xu
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5134-7

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue

Original Article

MiR-384 regulated IRS1 expression and suppressed cell proliferation of human hepatocellular carcinoma

Original Article

Proteomic analysis of differentially expressed proteins in vitreous humor of patients with retinoblastoma using iTRAQ-coupled ESI-MS/MS approach

Original Article

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

Original Article

Gene/protein expression of CAPN1/2-CAST system members is associated with ERK1/2 kinases activity as well as progression and clinical outcome in human laryngeal cancer

Original Article

Mucin-1 correlates with survival, smoking status, and growth patterns in lung adenocarcinoma

Original Article

Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits